1
Home
Companies

Nuvectis Pharma

#8182

Rank

$237.37M

Marketcap

US United States

Country

Nuvectis Pharma
Leadership team

Dr. Enrique Poradosu Ph.D. (Co-Founder, Exec. VP, Chief Scientific & Bus. Officer)

Mr. Shay Shemesh (Co-Founder, EVP, Chief Devel. & Operations Officer)

Mr. Ron Bentsur M.B.A. (Co-Founder, Chairman, CEO & Pres)

Products/ Services
Biopharma, Biotechnology, Health Care, Pharmaceutical
Headquarters
Fort Lee, New Jersey, United States
Established
2020
Company Registration
SEC CIK number: 0001875558
Traded as
NVCT
URL
https://www.nuvectis.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
History

Nuvectis Pharma was founded in 2015 with a mission to develop innovative drugs to address unmet medical needs. Since then, the company has grown rapidly and now has an extensive pipeline of new medicines in development, targeting areas such as cancer, rare diseases, and immune-mediated diseases. The company has established partnerships with leading institutions such as the National Institutes of Health, the University of Pennsylvania, and Memorial Sloan Kettering Cancer Center.

Mission
Our mission is to develop innovative treatments that make a meaningful difference in the lives of patients.
Vision
Our vision is to be the leading innovator in the biopharmaceutical industry, exploring new frontiers in personalized medicine and transforming lives around the world.
Key Team

Mr. Michael Carson CPA (VP of Fin.)

Recognition and Awards
Nuvectis has been recognized for its efforts in drug development and innovation across a wide range of diseases. Most recently, the company received a Gold award from the Centers for Disease Control and Prevention for its work tackling infectious disease.
References

https://in.investing.com/equities/nuvectis-pharma

https://finance.yahoo.com/quote/NVCT/profile?p=NVCT

https://www.crunchbase.com/organization/nuvectis-pharma

https://companiesmarketcap.com/

https://www.nuvectis.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Nuvectis Pharma
Leadership team

Dr. Enrique Poradosu Ph.D. (Co-Founder, Exec. VP, Chief Scientific & Bus. Officer)

Mr. Shay Shemesh (Co-Founder, EVP, Chief Devel. & Operations Officer)

Mr. Ron Bentsur M.B.A. (Co-Founder, Chairman, CEO & Pres)

Products/ Services
Biopharma, Biotechnology, Health Care, Pharmaceutical
Headquarters
Fort Lee, New Jersey, United States
Established
2020
Company Registration
SEC CIK number: 0001875558
Traded as
NVCT
URL
https://www.nuvectis.com